ALX Oncology Holdings Inc.
ALXO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.17 | -0.08 | -0.17 |
| FCF Yield | -140.43% | -20.57% | -19.76% | -8.43% |
| EV / EBITDA | -0.65 | -4.01 | -3.45 | -6.03 |
| Quality | ||||
| ROIC | -108.24% | -81.20% | -45.50% | -22.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.81 | 0.72 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 7.05% | -45.22% | -24.14% | -90.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.03 | 0.31 | 4.35 |
| Interest Coverage | -82.40 | -108.80 | -535.45 | -6,427.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.08 | 0.00 |
| Cash Conversion Cycle | -1,882.35 | -3,750.86 | -6,416.63 | -1,866.66 |